A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
Clinical trial NCT07090954 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07090954
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-31
- Primary completion
- 2026-07-31
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.